The BareStory
Biotechnology firm Metsera announced on Tuesday that it considers a new acquisition bid from Novo Nordisk, valued at up to $10 billion, to be "superior" to a revised offer from Pfizer worth approximately $8.1 billion. The announcement marks a significant escalation in the bidding war between the two pharmaceutical giants for control of the obesity-focused startup.
The new offers were revealed one day after Pfizer filed a second lawsuit against both Novo Nordisk and Metsera. In its legal action, Pfizer has alleged that Novo Nordisk's pursuit of Metsera is anticompetitive and an attempt to eliminate a potential competitor in the weight-loss drug market. Pfizer’s CEO, Albert Bourla, reportedly called Novo Nordisk’s offer “illusory” and in violation of antitrust law.
In response to the lawsuits, Novo Nordisk has called Pfizer’s claims “baseless” and “false,” stating that its proposal complies with all laws. Metsera said that Pfizer is “trying to litigate its way to buying Metsera for a lower price.”
The conflict began after Pfizer reached an initial agreement in September to acquire Metsera for $4.9 billion. Novo Nordisk later launched a competing bid, leading to the current standoff. The acquisition is seen as a key opportunity for Pfizer to enter the lucrative obesity drug market after struggling to develop its own products. Novo Nordisk, an established player in the sector, is facing increased competition from rival Eli Lilly.
Under the terms of its original merger agreement with Pfizer, Metsera must allow Pfizer a two-business-day period to adjust its proposal. If Metsera’s board still finds Novo Nordisk's bid to be better after that window, it can terminate the agreement with Pfizer.
How it may affect me
As a U.S. reader:
• The outcome may determine the level of competition in the weight-loss drug market, which could affect future consumer prices and treatment availability.
• This acquisition could accelerate the development of new obesity drugs, potentially making more treatment options available to the public sooner regardless of which company wins.
• The legal battle over antitrust claims could influence how future pharmaceutical mergers are regulated, potentially shaping long-term market dynamics and consumer choice.
